Cellmid Limited (ASX:CDY) is a listed Australian biotechnology company committed to the commercialization of midkine, a heparin-binding growth factor, and its inhibitors for both therapeutic and diagnostic applications.
CDY is actively looking for partners to commercialise the Company’s significant anti-midkine antibody portfolio for diagnostic and therapeutic purposes. In addition, CDY will also be looking for partnerships to continue to research anti-midkine antisense and siRNA.
CDY holds the largest intellectual property portfolio globally in relation to midkine, a significant therapeutic and diagnostic target.